ATE270882T1 - 3r-3'r diastereoisomer von zeaxanthin zur behandlung von der degeneration der macula - Google Patents

3r-3'r diastereoisomer von zeaxanthin zur behandlung von der degeneration der macula

Info

Publication number: ATE270882T1
Authority: AT; Austria
Prior art keywords: zeaxanthin; cells; stereoisomer; vitamin; isomer
Prior art date: 1995-10-31

Application number

AT96307928T

Other languages

English (en)

Inventor

Kevin M Garnett

Dennis L Gierhart

Luis H Guerra-Santos

Original Assignee

Zeavision L L C

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-31

Filing date

1996-10-31

Publication date

2004-07-15

1995-10-31 Priority claimed from US08/550,665 external-priority patent/US5747544A/en

1995-10-31 Priority claimed from US08/551,166 external-priority patent/US5854015A/en

1995-10-31 Priority claimed from US08/551,153 external-priority patent/US5827652A/en

1996-10-31 Application filed by Zeavision L L C filed Critical Zeavision L L C

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE270882T1 publication Critical patent/ATE270882T1/de

Links

JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 title abstract 5
JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 title abstract 5
QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 title abstract 5
JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 title abstract 5
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title abstract 5
229940043269 zeaxanthin Drugs 0.000 title abstract 5
235000010930 zeaxanthin Nutrition 0.000 title abstract 5
239000001775 zeaxanthin Substances 0.000 title abstract 5
230000007850 degeneration Effects 0.000 title 1
208000002780 macular degeneration Diseases 0.000 abstract 2
229940088594 vitamin Drugs 0.000 abstract 2
229930003231 vitamin Natural products 0.000 abstract 2
239000011782 vitamin Substances 0.000 abstract 2
150000003722 vitamin derivatives Chemical class 0.000 abstract 2
241001136276 Sphingobacterium multivorum Species 0.000 abstract 1
206010064930 age-related macular degeneration Diseases 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
235000015872 dietary supplement Nutrition 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
229940126585 therapeutic drug Drugs 0.000 abstract 1
235000013343 vitamin Nutrition 0.000 abstract 1
235000019195 vitamin supplement Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Botany (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Polymers & Plastics (AREA)
Dispersion Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

AT96307928T 1995-10-31 1996-10-31 3r-3'r diastereoisomer von zeaxanthin zur behandlung von der degeneration der macula ATE270882T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/550,665 US5747544A (en)	1995-10-31	1995-10-31	Method of using pure 3R-3'R stereoisomer of zeaxanthin to treat or prevent retinal degeneration in humans
US08/551,166 US5854015A (en)	1995-10-31	1995-10-31	Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
US08/551,153 US5827652A (en)	1995-10-31	1995-10-31	Zeaxanthin formulations for human ingestion

Publications (1)

Publication Number	Publication Date
ATE270882T1 true ATE270882T1 (de)	2004-07-15

Family

ID=27415594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96307928T ATE270882T1 (de)	1995-10-31	1996-10-31	3r-3'r diastereoisomer von zeaxanthin zur behandlung von der degeneration der macula

Country Status (7)

Country	Link
EP (1)	EP0774251B1 (de)
AT (1)	ATE270882T1 (de)
CA (1)	CA2188983C (de)
DE (1)	DE69632898T2 (de)
DK (1)	DK0774251T3 (de)
ES (1)	ES2225863T3 (de)
TW (1)	TW586930B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL1010351C2 (nl) *	1998-10-19	2001-01-08	Werklust & Beheer B V	Esters van caroteno´den voor gebruik in de preventie en behandeling van oogaandoeningen.
US20030228392A1 (en)	2002-06-06	2003-12-11	Wyeth	Infant formula compositions containing lutein and zeaxanthin
US9192586B2 (en)	2003-03-10	2015-11-24	Zeavision Llc	Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20090118227A1 (en)	2007-11-07	2009-05-07	Bristol-Myers Squibb Company	Carotenoid-containing compositions and methods
PL2473065T3 (pl)	2009-09-02	2017-02-28	Omniactive Health Technologies Ltd.	Kompozycja ksantofilowa zawierająca pigmenty plamki żółtej i sposób jej wytwarzania

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3891504A (en)	1970-07-31	1975-06-24	Hoffmann La Roche	Process for the manufacture of zeaxanthin
BE790289A (fr)	1971-10-27	1973-02-15	Nestle Sa	Procede de fabrication de zeaxanthine
CH572981A5 (de)	1973-07-26	1976-02-27	Nestle Sa
US4153615A (en)	1978-03-27	1979-05-08	Hoffmann-La Roche Inc.	Method of producing coloring agents
DE3119383A1 (de)	1981-05-15	1982-12-02	Basf Ag, 6700 Ludwigshafen	Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US4737462A (en)	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4675140A (en)	1984-05-18	1987-06-23	Washington University Technology Associates	Method for coating particles or liquid droplets
US4851339A (en)	1986-04-01	1989-07-25	Hills Christopher B	Extraction of anti-mutagenic pigments from algae and vegetables
DK171297B1 (da)	1987-03-27	1996-08-26	Hoffmann La Roche	Fremgangsmåde til fremstilling af cyclohexenderivater som mellemprodukter til fremstilling af zeaxanthin samt cyclohexenderivater
US5227507A (en)	1987-03-27	1993-07-13	Hoffmann-La Roche Inc.	Ethynylcyclohexene compounds and processes for manufacture thereof
US5180747A (en)	1989-02-28	1993-01-19	Nisshin Flour Milling Co., Ltd.	Stabilized fat-soluble vitamin compositions
US5429939A (en)	1989-04-21	1995-07-04	Kirin Beer Kabushiki Kaisha	DNA sequences useful for the synthesis of carotenoids
EP0393690B1 (de) *	1989-04-21	1995-03-29	Kirin Beer Kabushiki Kaisha	Zur Synthese von Karotinoiden verwendbare DNA-Sequenzen
US5290605A (en) *	1989-06-29	1994-03-01	Niva Shapira	Sun-exposure nutritional supporting composition
EP0534955B1 (de)	1989-08-30	1997-05-28	Applied Food Biotechnology, Inc.	Verfahren zur Herstellung einer Zeaxanthin enthaltenden Zusammensetzung mittels eines Mikroorganismus der Spezies Flavobacterium multivorum
DE4141351A1 (de)	1991-12-14	1993-06-17	Basf Ag	Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung
DE4200728A1 (de)	1992-01-14	1993-07-15	Basf Ag	Stabile, fluessige praeparate fettloeslicher substanzen
US5310764A (en)	1992-05-08	1994-05-10	Steven Baranowitz	Treatment of age related macular degeneration with beta-carotene
US5382714A (en)	1994-03-17	1995-01-17	The Catholic University Of America	Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
DE69636951T2 (de) *	1995-06-07	2007-11-22	The Howard Foundation, Cambridge	Pharmazeutisch aktive karotenoide

1996
- 1996-10-28 CA CA002188983A patent/CA2188983C/en not_active Expired - Lifetime
- 1996-10-31 EP EP96307928A patent/EP0774251B1/de not_active Expired - Lifetime
- 1996-10-31 DE DE69632898T patent/DE69632898T2/de not_active Expired - Lifetime
- 1996-10-31 ES ES96307928T patent/ES2225863T3/es not_active Expired - Lifetime
- 1996-10-31 DK DK96307928T patent/DK0774251T3/da active
- 1996-10-31 AT AT96307928T patent/ATE270882T1/de not_active IP Right Cessation
- 1996-11-28 TW TW085114674A patent/TW586930B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
TW586930B (en)	2004-05-11
EP0774251B1 (de)	2004-07-14
ES2225863T3 (es)	2005-03-16
EP0774251A3 (de)	1997-06-18
CA2188983A1 (en)	1997-05-01
DK0774251T3 (da)	2004-11-22
EP0774251A2 (de)	1997-05-21
CA2188983C (en)	2001-02-27
DE69632898D1 (de)	2004-08-19
DE69632898T2 (de)	2005-08-04

Legal Events

Date	Code	Title	Description
2005-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
AU6586896A (en)	1997-04-10	Fatty acid treatment
ATE136030T1 (de)	1996-04-15	Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
DE69636343D1 (de)	2006-08-24	Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69232485D1 (de)	2002-04-18	VERWENDUNG VON RELAXIN zur Herstellung eines Arzneimittels für die Behandlung KARDIOVASKULÄREN Krankeiten.
KR940018089A (ko)	1994-08-16	내부조직의 방사선 손상에 대한 예방 및 처치방법
ATE270882T1 (de)	2004-07-15	3r-3'r diastereoisomer von zeaxanthin zur behandlung von der degeneration der macula
MD1633B2 (en)	2001-03-31	Application of lysozyme dimer and method of non-specific cellular and humoral stimulation of mechanisms for immune system protection and for prophylaxis and treatment of immunodepressant state or diseases relating to it
ATE192923T1 (de)	2000-06-15	Verwendung von boswelliasäure zur behandlung von hirntumoren
ATE110274T1 (de)	1994-09-15	Mittel zur verbesserung spezifischer eigenschaften des blutes.
Gordon	1981	Elderly depressives: treatment and follow-up
JP2000143546A (ja)	2000-05-23	メラトニンの酸化分解抑制剤
ATE283060T1 (de)	2004-12-15	Verwendung einer pollenextrakt-haltigen verbindung zur behandlung hormon-assoziierter erkrankungen
HUP9902421A2 (hu)	1999-11-29	Nyálkahártya-viszkozitást optimalizáló és bélfunkciót stimuláló hatású készítmények
DE1667887B1 (de)	1971-10-07	Aminosaeureloesungen zur parenteralen Infusion
FI980947A7 (fi)	1998-04-29	Zeaksantiinin puhdas 3R-3'R-stereoisomeeri silmän keltatäplämuutoksen hoitamiseksi
EP0402208B1 (de)	1994-01-12	Mischung von Vitamin A in physiologischer Dosis und verschiedenen Wirkstoffen mit therapeutischer Wirksamkeit
US5904926A (en)	1999-05-18	Weight loss compound and method of using
WO2024166099A1 (en)	2024-08-15	Method of treating raynaud's conditions or erectile dysfunction
WO2023048673A1 (en)	2023-03-30	Blood and cell renewing natural mixture
UA10235A (uk)	1996-12-25	Спосіб корекції дезадаптаційних розладів організму
Zagorouiko et al.	2009	The Dietary Grape Polyphenol Concentrate “ENOANT” Enables Protection Against Biological Agents
AT13410U1 (de)	2013-12-15	Verwendung einer Ubiquinon-Komponente und ein Kombinationspräparat zur Verbesserung der weiblichen Fertilität
Fayed	2016	Stress and Autoimmune Diseases
Simon	1997	Weight-loss and sodium-reduction programmes reduced BP and the risk for hypertension in overweight adults with high-normal BP
Mertz	1996	Risk Assessment for Essential Trace Elements in Humans